306 related articles for article (PubMed ID: 17928466)
41. Individualization of mycophenolate mofetil dose in renal transplant recipients.
van Hest RM; Hesselink DA; Vulto AG; Mathot RA; van Gelder T
Expert Opin Pharmacother; 2006 Mar; 7(4):361-76. PubMed ID: 16503809
[TBL] [Abstract][Full Text] [Related]
42. Enteric-coated mycophenolate sodium for transplant immunosuppression.
Ingle GR; Shah T
Am J Health Syst Pharm; 2005 Nov; 62(21):2252-9. PubMed ID: 16239415
[TBL] [Abstract][Full Text] [Related]
43. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic prospective multicenter study.
Nashan B; Ivens K; Suwelack B; Arns W; Abbud Filho M; ;
Transplant Proc; 2004 Mar; 36(2 Suppl):521S-523S. PubMed ID: 15041400
[TBL] [Abstract][Full Text] [Related]
44. Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring.
Budde K; Tedesco-Silva H; Pestana JM; Glander P; Neumayer HH; Felipe CR; Machado PP; Sechaud R; Schmouder R
Ther Drug Monit; 2007 Jun; 29(3):381-4. PubMed ID: 17529899
[TBL] [Abstract][Full Text] [Related]
45. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation.
Hale MD; Nicholls AJ; Bullingham RE; Hené R; Hoitsma A; Squifflet JP; Weimar W; Vanrenterghem Y; Van de Woude FJ; Verpooten GA
Clin Pharmacol Ther; 1998 Dec; 64(6):672-83. PubMed ID: 9871432
[TBL] [Abstract][Full Text] [Related]
46. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children.
Reyes H; Hernández AM; Valverde S; Cataneo A; Mendoza A; Barrera I; Ortíz L; García-Roca P; Lopéz-Martínez B; Castañeda-Hernández G; Medeiros M
Pediatr Transplant; 2010 Sep; 14(6):746-52. PubMed ID: 20412508
[TBL] [Abstract][Full Text] [Related]
48. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil.
Prémaud A; Debord J; Rousseau A; Le Meur Y; Toupance O; Lebranchu Y; Hoizey G; Le Guellec C; Marquet P
Clin Pharmacokinet; 2005; 44(8):837-47. PubMed ID: 16029068
[TBL] [Abstract][Full Text] [Related]
49. Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience.
Rhu J; Lee KW; Park H; Park JB; Kim SJ; Choi GS
Ann Transplant; 2017 Nov; 22():707-718. PubMed ID: 29180612
[TBL] [Abstract][Full Text] [Related]
50. Orthotopic Heart Transplant Recipient with Enteric-coated Mycophenolate Sodium (Myfortic) Induced Colitis.
Morris CC; Stroud SC; Golconda U; Gregoire SA; Juneman EB
Am J Case Rep; 2020 May; 21():e920235. PubMed ID: 32404861
[TBL] [Abstract][Full Text] [Related]
51. Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients.
Cattaneo D; Merlini S; Baldelli S; Bartolini B; Nicastri A; Gotti E; Remuzzi G; Perico N
Ther Drug Monit; 2006 Oct; 28(5):643-9. PubMed ID: 17038879
[TBL] [Abstract][Full Text] [Related]
52. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study.
Dumortier J; Gagnieu MC; Salandre J; Guillaud O; Guillem P; Adham M; Boillot O
Liver Transpl; 2006 Sep; 12(9):1342-6. PubMed ID: 16741931
[TBL] [Abstract][Full Text] [Related]
53. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies.
Pietruck F; Abbud-Filho M; Vathsala A; Massari PU; Po-Huang L; Nashan B
Transplant Proc; 2007; 39(1):103-8. PubMed ID: 17275484
[TBL] [Abstract][Full Text] [Related]
54. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients.
Kamar N; Rostaing L; Cassuto E; Villemain F; Moal MC; Ladrière M; Barrou B; Ducloux D; Chaouche K; Quéré S; Di Giambattista F; Be F
Clin Nephrol; 2012 Feb; 77(2):126-36. PubMed ID: 22257543
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients.
Perry TW; Christians U; Trotter JF; Bendrick-Peart J
Clin Transplant; 2007; 21(3):413-6. PubMed ID: 17488394
[TBL] [Abstract][Full Text] [Related]
56. Mycophenolic acid in kidney transplant patients with diabetes mellitus: does the formulation matter?
Bolin P; Gohh R; Kandaswamy R; Shihab FS; Wiland A; Akhlaghi F; Melancon K
Transplant Rev (Orlando); 2011 Jul; 25(3):117-23. PubMed ID: 21530217
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients.
Budde K; Bauer S; Hambach P; Hahn U; Röblitz H; Mai I; Diekmann F; Neumayer HH; Glander P
Am J Transplant; 2007 Apr; 7(4):888-98. PubMed ID: 17391132
[TBL] [Abstract][Full Text] [Related]
58. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium.
Kamar N; Oufroukhi L; Faure P; Ribes D; Cointault O; Lavayssiere L; Nogier MB; Esposito L; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Oct; 20(10):2231-6. PubMed ID: 16046517
[TBL] [Abstract][Full Text] [Related]
59. Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients.
Tornatore KM; Sudchada P; Attwood K; Wilding GE; Gundroo AC; DiFrancesco R; Gray V; Venuto RC
J Clin Pharmacol; 2013 Mar; 53(3):285-93. PubMed ID: 23444283
[TBL] [Abstract][Full Text] [Related]
60. Mycophenolate revisited.
van Gelder T; Hesselink DA
Transpl Int; 2015 May; 28(5):508-15. PubMed ID: 25758949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
